Voyager Therapeutics, Inc. Class Action Lawsuit
- Company Name
- Voyager Therapeutics, Inc.
- Stock Symbol
- Class Period
- June 1, 2017 to November 9, 2020
- Motion Deadline
- March 24, 2021
- Eastern District of New York
The Voyager Therapeutics, Inc. class action lawsuit charges Voyager Therapeutics and certain of its executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers or acquirers of Voyager Therapeutics securities between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”). The Voyager Therapeutics class action lawsuit was commenced on January 22, 2021 in the Eastern District of New York and is captioned Karp v. Voyager Therapeutics, Inc., No. 21-cv-00381.
Voyager Therapeutics, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. Included in Voyager Therapeutics’ pre-clinical programs is VY-HTT01 for Huntington’s disease. In September 2020, Voyager Therapeutics submitted an investigational new drug (“IND”) application for VY-HTT01 for the treatment of Huntington’s disease to the U.S. Food and Drug Administration (“FDA”).
The Voyager Therapeutics class action lawsuit alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Voyager Therapeutics’ VY-HTT01 IND submission to the FDA lacked key information regarding certain chemistry, manufacturing, and controls (“CMC”) matters, including, among other things, drug-device compatibility and drug substance and product characterization; (ii) Voyager Therapeutics’ IND submission for VY-HTT01 was therefore deficient; (iii) Voyager Therapeutics had thus materially overstated the likelihood of FDA approval for VY-HTT01 based on the IND submission; and (iv) as a result, Voyager Therapeutics’ public statements were materially false and misleading at all relevant times.
On October 12, 2020, Voyager Therapeutics issued a press release disclosing that it “has received feedback from the [FDA] on the [IND] submission for VY-HTT01 for the treatment of Huntington’s disease.” Specifically Voyager Therapeutics advised investors that it “has been notified that the IND was placed on clinical hold pending the resolution of certain [CMC] matters.” Then, on November 9, 2020, Voyager Therapeutics disclosed that, with respect to its IND application for VY-HTT01, “Voyager recently received written feedback from the FDA requesting additional information on specific CMC topics, including drug-device compatibility and drug substance and product characterization.” On this news, Voyager Therapeutics’ stock price fell by more than 23%, damaging investors.
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Voyager Therapeutics securities during the Class Period to seek appointment as lead plaintiff in the Voyager Therapeutics class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Voyager Therapeutics class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Voyager Therapeutics class action lawsuit. An investor’s ability to share in any potential future recovery of the Voyager Therapeutics class action lawsuit is not dependent upon serving as lead plaintiff. If you wish to serve as lead plaintiff of the Voyager Therapeutics class action lawsuit or have questions concerning your rights regarding the Voyager Therapeutics class action lawsuit, please provide your information here or contact counsel, J.C. Sanchez of Robbins Geller, at 800/449-4900 or 619/231-1058 or via e-mail at email@example.com. Lead plaintiff motions for the Voyager Therapeutics class action lawsuit must be filed with the court no later than March 24, 2021.
Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities class action litigation. With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history. For seven consecutive years, ISS Securities Class Action Services has ranked the Firm in its annual SCAS Top 50 Report as one of the top law firms in the world in both amount recovered for shareholders and total number of class action settlements. Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims. Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide. Robbins Geller attorneys are consistently recognized by courts, professional organizations and the media as leading lawyers in the industry.